Pinealon

It's like a promising sketch on a research whiteboard that someone has photocopied and is selling as a finished blueprint. The underlying drawings (cell and rat experiments) are real and intriguing, but no one has actually built and tested the thing in humans, and almost every drawing comes from the same one studio.

Pinealon is the tripeptide Glu-Asp-Arg (EDR). Its proposed mechanism, per the Khavinson group, is that very short peptides enter cells and the nucleus and bind directly to specific DNA sequences (CG-rich promoter sites) and histones, acting as epigenetic regulators that switch target genes on or off. In neuronal models this is reported to upregulate antioxidant-enzyme genes (e.g. SOD2, catalase), reduce apoptosis markers (caspase-3), lower reactive oxygen species and preserve mitochondrial function and synaptic structure. This direct DNA-interaction model is mechanistically unusual and not independently established. The antioxidant and anti-apoptotic effects are documented mainly in vitro and in rodents.

Research contexts. Not proven uses, and not recommendations.

Very thin to non-existent. There are no completed, registered, independent randomised controlled trials of Pinealon/EDR for any neurological or cognitive outcome. The published literature is dominated by in-vitro neuronal cultures, rodent hypoxia and Alzheimer's-type models, and mechanistic/epigenetic hypothesis papers, with almost all originating from the Khavinson group and affiliated Russian institutions. Claims of human cognitive, memory or longevity benefit should not be treated as demonstrated in people.

• !No meaningful human efficacy or safety data. Benefits are inferred from cells and rodents only.
• !Near-total reliance on a single research group with little independent replication. Publication-bias and reproducibility concerns are significant.
• !Sold as an unlicensed grey-market 'research chemical', usually labelled 'not for human consumption'; no UK marketing authorisation.
• !Grey-market products have no guarantee of identity, purity, sterility or endotoxin content. Injectable peptides carry infection and contamination risks.
• !The proposed 'peptide binds DNA directly to regulate genes' mechanism is contested and not well established outside the originating group.
• !Long-term effects of chronic gene expression manipulation in the brain are entirely unstudied in humans.

Pinealon is not a licensed medicine in the UK and holds no MHRA marketing authorisation. It is not an approved or recognised treatment for any condition, and there are no MHRA-authorised clinical trials of it. In practice it is sold online as an unlicensed "research chemical", typically labelled "not for human consumption" to sidestep medicines regulation. Selling or supplying it for human use would engage the Human Medicines Regulations 2012. It is not something a UK clinician can lawfully prescribe as a recognised therapy.

1. 01
   EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease — Khavinson V, Linkova N, Kozhevnikova E, Trofimova S, Molecules (2021)

   Mechanistic/hypothesis review proposing how the EDR (Pinealon) tripeptide may regulate gene expression in an Alzheimer's context. Preclinical/theoretical, from the originating group.

2. 02
   Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease — Ilina A, Khavinson V, Linkova N, Petukhov M, International Journal of Molecular Sciences (2022)

   Review of proposed epigenetic mechanisms (DNA/histone interaction) of short peptides including EDR; hypothesis-generating, not clinical evidence.

3. 03
   Peptide Regulation of Gene Expression: A Systematic Review — Khavinson V, Popovich I, Linkova N, Mironova E, Ilina A, Molecules (2021)

   Systematic review from the originating group framing the short-peptide/DNA-methylation hypothesis; useful for understanding the claimed mechanism, but largely self-referential.

4. 04
   Search: Pinealon / EDR peptide neuroprotection (PubMed), PubMed

   Live search to gauge the small, single-group-dominated primary literature base.